FDA sonefpeglutide coverage for business development, investment, and market access teams
Hanmi Pharmaceutical has announced a significant licensing deal with Eli Lilly for its biologic drug candidate, sonefpeglutide. This agreement grants Lilly global rights, excluding Korea, and includes substantial upfront and milestone payments.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
